Clinical Spectrum of LMNA-Associated Type 2 Familial Partial Lipodystrophy: A Systematic Review

被引:20
|
作者
Fernandez-Pombo, Antia [1 ,2 ]
Diaz-Lopez, Everardo Josue [1 ,2 ]
Castro, Ana I. [2 ,3 ]
Sanchez-Iglesias, Sofia [1 ]
Cobelo-Gomez, Silvia [1 ]
Prado-Morana, Teresa [1 ,2 ]
Araujo-Vilar, David [1 ,2 ]
机构
[1] Univ Santiago De Compostela, Dept Psychiat Radiol Publ Hlth Nursing & Med, UETeM Mol Pathol Grp, IDIS CIMUS, Santiago De Compostela 15706, Spain
[2] Univ Clin Hosp Santiago De Compostela, Div Endocrinol & Nutr, Santiago De Compostela 15706, Spain
[3] CIBER Fisiopatol Obes & Nutr CIBERobn, Madrid 28029, Spain
关键词
LMNA; Dunnigan disease; type 2 familial partial lipodystrophy; laminopathies; FPLD2; MULTIPLE SYMMETRIC LIPOMATOSIS; ACTIVATED RECEPTOR-GAMMA; LAMIN A/C LMNA; DUNNIGAN-TYPE; ADIPOSE-TISSUE; INSULIN-RESISTANCE; MISSENSE MUTATIONS; R482W MUTATION; NUCLEAR LAMIN; MANDIBULOACRAL DYSPLASIA;
D O I
10.3390/cells12050725
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Type 2 familial partial lipodystrophy (FPLD2) is a laminopathic lipodystrophy due to pathogenic variants in the LMNA gene. Its rarity implies that it is not well-known. The aim of this review was to explore the published data regarding the clinical characterisation of this syndrome in order to better describe FPLD2. For this purpose, a systematic review through a search on PubMed until December 2022 was conducted and the references of the retrieved articles were also screened. A total of 113 articles were included. FPLD2 is characterised by the loss of fat starting around puberty in women, affecting limbs and trunk, and its accumulation in the face, neck and abdominal viscera. This adipose tissue dysfunction conditions the development of metabolic complications associated with insulin resistance, such as diabetes, dyslipidaemia, fatty liver disease, cardiovascular disease, and reproductive disorders. However, a great degree of phenotypical variability has been described. Therapeutic approaches are directed towards the associated comorbidities, and recent treatment modalities have been explored. A comprehensive comparison between FPLD2 and other FPLD subtypes can also be found in the present review. This review aimed to contribute towards augmenting knowledge of the natural history of FPLD2 by bringing together the main clinical research in this field.
引用
收藏
页数:23
相关论文
共 50 条
  • [1] LMNA-associated partial lipodystrophy: anticipation of metabolic complications
    Jeru, Isabelle
    Vatier, Camille
    Vantyghem, Marie-Christine
    Lascols, Olivier
    Vigouroux, Corinne
    JOURNAL OF MEDICAL GENETICS, 2017, 54 (06) : 413 - 416
  • [2] Hepatic Steatosis Resulting From LMNA-Associated Familial Lipodystrophy
    Mahdi, Layth
    Kahn, Allon
    Dhamija, Radhika
    Vargas, Hugo E.
    ACG CASE REPORTS JOURNAL, 2020, 7 (04)
  • [3] Irisin levels in LMNA-associated partial lipodystrophies
    Bensmaine, F.
    Benomar, K.
    Espiard, S.
    Vahe, C.
    Le Mapihan, K.
    Lion, G.
    Lemdani, M.
    Chazard, E.
    Ernst, O.
    Vigouroux, C.
    Pigny, P.
    Vantyghem, M. -C.
    DIABETES & METABOLISM, 2019, 45 (01) : 67 - 75
  • [4] Potential association of LMNA-associated generalized lipodystrophy with juvenile dermatomyositis
    Melis Sahinoz
    Shafaq Khairi
    Ashley Cuttitta
    Graham F. Brady
    Amit Rupani
    Rasimcan Meral
    Marwan K. Tayeh
    Peedikayil Thomas
    Meredith Riebschleger
    Sandra Camelo-Piragua
    Jeffrey W. Innis
    M. Bishr Omary
    Daniel E. Michele
    Elif A. Oral
    Clinical Diabetes and Endocrinology, 4 (1):
  • [5] Cardiac laminopathy in familial partial lipodystrophy type 2 secondary to variants in the LMNA gene
    Moreno Tirado, Antonio
    Rodriguez Ortega, Pilar
    Calle Isorna, Jose Maria
    MEDICINA CLINICA, 2024, 163 (12): : 634 - 635
  • [6] Familial partial lipodystrophy associated with compound heterozygosity for novel mutations in the LMNA gene
    D. B. Savage
    I. McFarlane
    I. Barroso
    M. A. Soos
    A. Powlson
    E. L. Thomas
    J. D. Bell
    I. Scobie
    P. E. Belchetz
    W. F. Kelly
    D. J. Halsall
    A. J. Schafer
    S. O’Rahilly
    Diabetologia, 2004, 47 : 753 - 756
  • [7] Familial partial lipodystrophy associated with compound heterozygosity for novel mutations in the LMNA gene
    Savage, DB
    Soos, MA
    Powlson, A
    O'Rahilly, S
    McFarlane, I
    Halsall, DJ
    Barroso, I
    Thomas, EL
    Bell, JD
    Scobie, I
    Belchetz, PE
    Kelly, WF
    Schafer, AJ
    DIABETOLOGIA, 2004, 47 (04) : 753 - 756
  • [8] A LMNA splicing mutation in two sisters with severe dunnigan-type familial partial lipodystrophy type 2
    Morel, Chantal F.
    Thomas, Mary Ann
    Cao, Henian
    O'Neil, Caroline H.
    Pickering, J. Geoffrey
    Foulkes, William D.
    Hegele, Robert A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (07): : 2689 - 2695
  • [9] Podocytopathies associated with familial partial lipodystrophy due to LMNA variants: report of two cases
    Morguetti, Maria Julia
    Neves, Precil Diego Miranda de Menezes
    Korkes, Ilana
    Padilha, Wallace Stwart Carvalho
    Jorge, Lecticia Barbosa
    Watanabe, Andreia
    Watanabe, Elieser Hitoshi
    Malheiros, Denise Maria Avancini Costa
    Noronha, Irene de Lourdes
    Dib, Sergio Atala
    Onuchic, Luiz Fernando
    Moises, Regina S.
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2024, 68
  • [10] Hypopharyngeal Squamous Cell Carcinoma in Sisters with LMNA Associated Familial Partial Lipodystrophy: A Case Report and Review of the Literature
    Youssef, Stephanie J.
    Macielak, Robert J.
    Schimmenti, Lisa A.
    Chatzopoulos, Kyriakos
    Price, Daniel L.
    ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2020, 129 (12): : 1243 - 1246